Daun02

$216$528

Products Details

Product Description

– Daun02 is a proagent of the topoisomerase inhibitor Daunorubicin.

Web ID

– HY-13061

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C41H44N2O20

References

– [1]Koya E, et al. Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization. Nat Neurosci. 2009 Aug;12(8):1069-73.|[2]Farquhar D, et al. Suicide gene therapy using E. coli beta-galactosidase.Cancer Chemother Pharmacol. Cancer Chemother Pharmacol. 2002 Jul;50(1):65-70.|[3]Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.

CAS Number

– 290304-24-4

Molecular Weight

– 884.79

Compound Purity

– 98.72

SMILES

– O[C@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)OC2=CC=C(C=C2[N+]([O-])=O)COC(N[C@@H]3[C@@H]([C@@H](O[C@H](C3)O[C@H]4C[C@](C(C)=O)(CC5=C(C(C(C6=C7C(OC)=CC=C6)=O)=C(C(O)=C54)C7=O)O)O)C)O)=O)CO

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : ≥ 100 mg/mL

Target

– ADC Cytotoxin;Topoisomerase

Isoform

– Daunorubicins/Doxorubicins;Topoisomerase

Pathway

– Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage

Product type

– ADC Related

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=